Emerging Opportunities in the Hormone Refractory Prostate Cancer...

agregó una foto Health

2026-10-01 08:59:08 -

Emerging Opportunities in the Hormone Refractory Prostate Cancer Hrpca Market by 2035

Genomic Profiling, PARP Inhibitors, and Theranostics Transformation The management of hormone-refractory disease is experiencing a major shift toward personalized oncology. Historical approaches relied heavily on standardized chemotherapy protocols once androgen blockade failed. Today, next-generation sequencing (NGS) enables clinicians to tailor regimens based on actionable genomic mutations...

0 Commentarios 0 Acciones 5 Views 0 Vista previa